Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $1.09 billion. The enterprise value is $882.60 million.
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, after market close.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 104.36 million shares outstanding. The number of shares has increased by 17.60% in one year.
| Current Share Class | 104.36M |
| Shares Outstanding | 104.36M |
| Shares Change (YoY) | +17.60% |
| Shares Change (QoQ) | +0.44% |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 91.20% |
| Float | 83.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 35.71 |
| PB Ratio | 2.89 |
| P/TBV Ratio | 4.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.05, with a Debt / Equity ratio of 0.08.
| Current Ratio | 6.05 |
| Quick Ratio | 5.89 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -145.40 |
Financial Efficiency
Return on equity (ROE) is -59.27% and return on invested capital (ROIC) is -37.13%.
| Return on Equity (ROE) | -59.27% |
| Return on Assets (ROA) | -34.48% |
| Return on Invested Capital (ROIC) | -37.13% |
| Return on Capital Employed (ROCE) | -77.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$962,981 |
| Employee Count | 268 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.44% in the last 52 weeks. The beta is 0.98, so RCKT's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -63.44% |
| 50-Day Moving Average | 11.27 |
| 200-Day Moving Average | 17.46 |
| Relative Strength Index (RSI) | 45.20 |
| Average Volume (20 Days) | 1,297,593 |
Short Selling Information
The latest short interest is 10.52 million, so 10.08% of the outstanding shares have been sold short.
| Short Interest | 10.52M |
| Short Previous Month | 11.70M |
| Short % of Shares Out | 10.08% |
| Short % of Float | 12.53% |
| Short Ratio (days to cover) | 6.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -273.79M |
| Pretax Income | -253.26M |
| Net Income | -258.08M |
| EBITDA | -264.84M |
| EBIT | -273.79M |
| Earnings Per Share (EPS) | -$2.75 |
Full Income StatementBalance Sheet
The company has $235.66 million in cash and $25.64 million in debt, giving a net cash position of $210.02 million or $2.01 per share.
| Cash & Cash Equivalents | 235.66M |
| Total Debt | 25.64M |
| Net Cash | 210.02M |
| Net Cash Per Share | $2.01 |
| Equity (Book Value) | 329.77M |
| Book Value Per Share | 3.62 |
| Working Capital | 201.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$192.12 million and capital expenditures -$10.20 million, giving a free cash flow of -$202.32 million.
| Operating Cash Flow | -192.12M |
| Capital Expenditures | -10.20M |
| Free Cash Flow | -202.32M |
| FCF Per Share | -$1.94 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |